Abstract

Autonomic dysfunction is a common non-motor symptom in Parkinson’s disease (PD). Dopamine and serotonin are known to play a role in autonomic regulation, and, therefore, PD-related degeneration of serotonergic and dopaminergic neurons in these regions may be associated with autonomic dysfunction. We sought to clarify the association between extrastriatal serotonergic and striatal dopaminergic degeneration and the severity of autonomic symptoms, including gastrointestinal, pupillomotor, thermoregulatory, cardiovascular, and urinary dysfunction. We performed hierarchical multiple regression analyses to determine the relationships between (extra)striatal serotonergic and dopaminergic degeneration and autonomic dysfunction in 310 patients with PD. We used [123I]FP-CIT SPECT binding to presynaptic serotonin (SERT) and dopamine (DAT) transporters as a measure of the integrity of these neurotransmitter systems, and the SCOPA-AUT (Scales for Outcomes in Parkinson’s Disease—Autonomic) questionnaire to evaluate the perceived severity of autonomic dysfunction. Motor symptom severity, medication status, and sex were added to the model as covariates. Additional analyses were also performed using five subdomains of the SCOPA-AUT: cardiovascular, gastrointestinal, urinary, thermoregulatory, and pupillomotor symptoms. We found that autonomic symptoms were most significantly related to lower [123I]FP-CIT binding ratios in the right caudate nucleus and were mainly driven by gastrointestinal and cardiovascular dysfunction. These results provide a first look into the modest role of dopaminergic projections towards the caudate nucleus in the pathophysiology of autonomic dysfunction in PD, but the underlying mechanism warrants further investigation.

Highlights

  • Besides the characteristic motor symptoms, Parkinson’s disease (PD) patients frequently suffer from a variety of non-motor complaints including cognitive decline, neuropsychiatric problems, and autonomic dysfunction [1]

  • Patients were excluded if they were taking any medication during the ­[123I]FP-CIT Single-photon emission computed tomography (SPECT) scan that could influence the ability of the ­[123I]FP-CIT tracer to bind to DAT or SERT, such as SSRIs or serotonin–norepinephrine reuptake inhibitors (SNRIs) [28]

  • To determine which autonomic symptoms drove the associations, post hoc analyses were performed with subdomains of the SCOPA-AUT. These results showed that the reported associations with the total SCOPA-AUT were mainly driven by cardiovascular and gastrointestinal symptoms

Read more

Summary

Introduction

Besides the characteristic motor symptoms, Parkinson’s disease (PD) patients frequently suffer from a variety of non-motor complaints including cognitive decline, neuropsychiatric problems, and autonomic dysfunction [1]. Serotonin (5-hydroxytryptamine; 5-HT) has an important role in the regulation of the autonomic nervous system (ANS). Serotonergic neurons originating from the nucleus raphe obscurus and raphe pallidus have projections to Journal of Neurology (2020) 267:1922–1930 autonomic nuclei in the medulla and spinal cord. These serotonergic neurons receive input from brain areas important for autonomic regulation in the brainstem, forebrain, and hypothalamus [7, 8]. Some myenteric neurons are dopaminergic, and dopamine affects gastrointestinal motility via presynaptic D2 receptors by inhibiting acetylcholine release [17]. Striatal D2 receptors are involved in the salivary response [19], the micturition reflex and detrusor activity [20], and central blood pressure and heart rate regulation [21]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call